Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

10.3%

7 terminated/withdrawn out of 68 trials

Success Rate

88.7%

+2.2% vs industry average

Late-Stage Pipeline

34%

23 trials in Phase 3/4

Results Transparency

53%

29 of 55 completed trials have results

Key Signals

1 recruiting29 with results4 withdrawn

Enrollment Performance

Analytics

Phase 2
20(34.5%)
Phase 3
15(25.9%)
N/A
8(13.8%)
Phase 4
8(13.8%)
Phase 1
7(12.1%)
58Total
Phase 2(20)
Phase 3(15)
N/A(8)
Phase 4(8)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (68)

Showing 20 of 68 trials
NCT05984927Phase 1Active Not Recruiting

NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration

Role: collaborator

NCT05411367Phase 3Completed

A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye

Role: collaborator

NCT06264232Not ApplicableCompleted

AT ELANA 841P Posterior Chamber Intraocular Lens for Correction of Aphakia Following Cataract Removal

Role: collaborator

NCT07068958Phase 2Not Yet Recruiting

A Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye

Role: lead

NCT05896670Phase 2Completed

Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease

Role: collaborator

NCT05841862Not ApplicableWithdrawn

Intravitreal Quantum Dots (QD) for Advanced Retinitis Pigmentosa (RP) (QUANTUM)

Role: collaborator

NCT03990051Phase 2Completed

Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.

Role: collaborator

NCT06812572Not ApplicableCompleted

A Prospective Clinical Study to Evaluate the Repeatability of the Visibly Vision Test

Role: collaborator

NCT05753189Phase 3Completed

Phase 3 Safety Study for the Treatment of Presbyopia Subjects

Role: collaborator

NCT06128369Phase 3Terminated

Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery

Role: collaborator

NCT05438732Not ApplicableRecruiting

Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD

Role: collaborator

NCT06329791Phase 3Active Not Recruiting

A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)

Role: collaborator

NCT02298400Not ApplicableWithdrawn

A Clinical Study Comparing the Comfort of Three Commercially Available Contact Lenses

Role: lead

NCT03275753Terminated

Visual Function Tests in Age-related Macular Degeneration

Role: lead

NCT03693183Phase 2Withdrawn

Efficacy Study of Ketorolac and HPMC to Treat Dry Eye

Role: lead

NCT05241470Phase 2Completed

Study of ST-100 as Treatment for Dry Eye Disease

Role: collaborator

NCT03088605Phase 2Completed

Safety and Efficacy of TOP1630 for Dry Eye Syndrome

Role: lead

NCT05759208Phase 2Completed

The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease

Role: collaborator

NCT06178679Phase 3Unknown

Safety and Efficacy of ST-100 (Vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed With Dry Eye Disease (DED)

Role: lead

NCT05936489Phase 1Completed

Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia

Role: collaborator